EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case report: EGFR-TKI rechallenge after osimertinib-induced interstitial lung disease: a case report and literature review

Xiaofei Gu, Yonghong Zhong, Huaqiong Huang

Frontiers in Pharmacology · 04.06.2024 · 15

DOI: 10.3389/fphar.2024.1410684 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 04.06.2024. Verfasst von Xiaofei Gu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Linping Campus, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangz…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), has demonstrated significant efficacy in treating non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. However, EGFR-TKI-induced interstitial lung disease (ILD), a well-known adverse effect, can seriously affect the treatment outcome. There is currently no international consensus on the efficacy and safety of re-administration of EGFR-TKI after EGFR-TKI-induced ILD. Case summary We report a case of a 62-year-old male with stage IV lung adenocarcinoma and EGFR L858R mutation who was treated with osimertinib at a dose of 80 mg/day as first-line therapy. On the sixth day of treatment, the patient developed grade 4 ILD, chest tightness, shortness of breath, and paroxysmal dry cough. Arterial blood gas analysis indicated the presence of type I respiratory failure, while the chest CT scan revealed newly developed ground-glass opacities in both lungs and a considerable amount of pleural effusion on the left side. Subsequently, the patient was administered methylprednisolone for anti-inflammatory therapy, in conjunction with oxygen therapy, anti-infection treatment, and closed thoracic drainage, which resulted in a favourable recovery and discharge after 18 days. During this period, the patient adhered to third-generation EGFR-TKI oral targeted therapy. Nevertheless, within a week of discharge, the patient was readmitted due to the recurrence of chest tightness and shortness of breath. A chest CT scan indicated a recurrent ILD. Despite the administration of high-dose methylprednisolone for 9 days, the patient’s condition continued to deteriorate, ultimately resulting in death.

Conclusion

It is of the utmost importance to conduct a meticulous evaluation of the severity of osimertinib-induced ILD in order to ascertain the potential risks and benefits of EGFR-TKI rechallenge. Particularly, for patients with grade 4 ILD, firm drug discontinuation should be considered.

Schlagwörter

Stichwörter der Autor:innen

epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)interstitial lung disease (ILD)non-small cell lung cancer (NSCLC)osimertinibrechallenge

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, Linping Campus, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
  • Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

Zitieren

APA

Gu, X., Zhong, Y., & Huang, H. (2024). Case report: EGFR-TKI rechallenge after osimertinib-induced interstitial lung disease: a case report and literature review. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1410684

Vancouver

Gu X, Zhong Y, Huang H. Case report: EGFR-TKI rechallenge after osimertinib-induced interstitial lung disease: a case report and literature review. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1410684

BibTeX
@article{Gu2024,
  author = {Gu, Xiaofei and Zhong, Yonghong and Huang, Huaqiong},
  title = {Case report: EGFR-TKI rechallenge after osimertinib-induced interstitial lung disease: a case report and literature review},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1410684}
}
Kostenlos starten →